CFHR1 is a potentially downregulated gene in lung adenocarcinoma

Abstract

There is increasing evidence that human complement factor H-related protein 1 (CFHR1) plays a crucial role in the development of malignant diseases. However, few studies have identified the roles of CFHR1 in the occurrence and prognosis of lung adenocarcinoma (LADC). In the present study, comprehensive bioinformatic analyses of data obtained from the Oncomine platform, UALCAN and Gene Expression Profiling Interactive Analysis (GEPIA) demonstrated that CFHR1 expression is significantly reduced in both LADC tissues and cancer cells. The patients presenting with downregulation of CFHR1 had significantly lower overall survival (OS) and post progression survival (PPS) times. Through analysis of the datasets from Gene Expression Omnibus database, we found that the compound actinomycin D promoted CFHR1 expression, further displaying the cytotoxic effect in the LADC cell line A549. In addition, the expression level of CFHR1 in the cisplatin-resistant LADC cell line CDDP-R (derived from H460) was also significantly reduced. Our research demonstrated that low levels of CFHR1 are specifically found in LADC samples, and CFHR1 could serve as a potential therapeutic target for this subset of lung cancers. Determination of the detailed roles of CFHR1 in LADC biology could provide insightful information for further investigations.

Protein-centric omics analysis reveals circulating complements linked to non-viral liver diseases as potential therapeutic targets

“…Therefore, it is conceivable that increased circulating concentrations of CFHR1 and CFHR2 may prevent people from developing ALC by inhibiting complement activation. Furthermore, studies have demonstrated that CFHR1 has relevance in malignancies such as lung adenocarcinoma and myelogenous leukemia [ 40 , 41 ]. Specifically, lung adenocarcinoma samples exhibit low levels of CFHR1 and deletion of both alleles of the CFHR1 gene has been identified as a potential predictor for the risk of developing acute myelogenous leukemia.…”

“…Furthermore, studies have demonstrated that CFHR1 has relevance in malignanhttp://www.e-cmh.org https://doi.org/10.3350/cmh.2023.0343 cies such as lung adenocarcinoma and myelogenous leukemia. 40,41 Specifically, lung adenocarcinoma samples exhibit low levels of CFHR1 and deletion of both alleles of the CFHR1 gene has been identified as a potential predictor for the risk of developing acute myelogenous leukemia. Additionally, our results indicate an association between C1QC and ALC risk.…”

Proteomic analysis reveals distinctive protein expression patterns of thrombus in clear cell renal cell carcinoma

“…A recent study has shown the function of CFHR1 in tumors: CFHR1 might potentially function as a tumor suppressor. The downregulation of CFHR1 was related to higher pathological T stage and shortened overall survival in patients with lung adenocarcinoma [ 30 ]. In this study, we also demonstrated the expression of CFHR1 in ccRCC tissues and thrombus tissues compared with normal kidney tissues, proving its important role in RCC thrombus formation.…”

Screening and identification of serum biomarkers of osteoarticular tuberculosis based on mass spectrometry

“…Studies have shown that CFHR1 plays a role in the prognosis of patients with lung adenocarcinoma. 26 The prognosis of lung adenocarcinoma patients with downregulated CFHR1 is generally poor, which also led to the idea that CFHR1 may be a target for tumor inhibition drugs. In addition, some studies have reported that deletion of CFHR1-related gene loci may lead to aggravation of pathogenic infections such as Andes orthohantavirus (ANDV) and Shiga toxin.…”